Price per share at which was offered in a registered direct offering.

No definition available.

Name:	nnvc_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights
Namespace Prefix:	nnvc_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Period for exercise of warrants.

+ References

No definition available.

+ Details

Name:	nnvc_ClassOfWarrantOrRightTerm
Namespace Prefix:	nnvc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of clinical trial costs.

+ References

No definition available.

+ Details

Name:	nnvc_ClinicalTrailCost
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of clinical trial costs incurred.

+ References

No definition available.

+ Details

Name:	nnvc_ClinicalTrailCostsIncurred
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of clinical trial commitment liability.

+ References

No definition available.

+ Details

Name:	nnvc_ClinicalTrialCommitmentLiability
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The number of shares to be issued pursuant to agreement.

+ References

No definition available.

+ Details

Name:	nnvc_NumberOfSharesToBeIssued
Namespace Prefix:	nnvc_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash outflow for clinical trial costs.

+ References

No definition available.

+ Details

Name:	nnvc_PaymentOfClinicalTrialCosts
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash inflow from issuance of common stock and warrants.

+ References

No definition available.

+ Details

Name:	nnvc_ProceedsFromIssuanceOfCommonStockAndWarrants
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of sales agent commission on aggregate gross proceeds.

+ References

No definition available.

+ Details

Name:	nnvc_SalesAgentCommissionPercentage
Namespace Prefix:	nnvc_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

Period for filing of registration statement after closing date under the securities purchase agreement.

+ References

No definition available.

+ Details

Name:	nnvc_SecuritiesPurchaseAgreementRegistrationStatementFilingPeriod
Namespace Prefix:	nnvc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Threshold restriction period on issue of shares under the securities purchase agreement.

+ References

No definition available.

+ Details

Name:	nnvc_SecuritiesPurchaseAgreementThresholdRestrictionPeriodOnSharesIssue
Namespace Prefix:	nnvc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.

+ References

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=nnvc_PreFundedWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=nnvc_RegisteredDirectOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=nnvc_CommonWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=nnvc_AtMarketSalesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=nnvc_July272026RegisteredDirectOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Subsequent Events (Details)						3 Months Ended
Subsequent Events (Details)	Jul. 27, 2026 USD ($)	Jul. 24, 2026 $ / shares shares	Jul. 17, 2026 $ / shares	May 18, 2026 USD ($) $ / shares	Nov. 10, 2025 USD ($) $ / shares shares	Sep. 28, 2026 USD ($)	Jun. 30, 2026 USD ($) $ / shares	May 15, 2026 $ / shares shares	Nov. 25, 2025 $ / shares	Jun. 30, 2025 $ / shares
Subsequent Events
Common stock, par value (in dollars per share)							$ 0.00001			$ 0.00001
Clinical trial commitment liability \| $							$ 0
Pre-Funded Warrants
Subsequent Events
Common stock, par value (in dollars per share)				$ 0.00001					$ 0.00001
Registered Direct Offering
Subsequent Events
Gross proceeds \| $				$ 2,000,000	$ 6,000,000
Registered Direct Offering \| Pre-Funded Warrants
Subsequent Events
Warrants to purchase additional shares (in shares) \| shares					1,601,429			200,000
Warrant issued price (in dollars per share)					$ 1.67999			$ 1.49999
Number of shares issuable upon exercise of each warrants issued \| shares					1			1
Exercise price (in dollars per share)					$ 0.00001			$ 0.00001
Registered Direct Offering \| Common Warrants
Subsequent Events
Warrants to purchase additional shares (in shares) \| shares								1,333,334
Exercise price (in dollars per share)								$ 1.75
Common Stock \| Registered Direct Offering
Subsequent Events
Common stock, par value (in dollars per share)					$ 0.00001			$ 0.00001
Number of shares to be issued (in shares) \| shares					1,970,000			1,133,334
Public offering price (in dollars per share)					$ 1.68
Subsequent Events
Subsequent Events
Clinical trial costs incurred \| $						$ 923,000
Payment of clinical trial costs \| $						923,000
Subsequent Events \| Forecast \| Minimum
Subsequent Events
Clinical trial cost \| $						2,500,000
Subsequent Events \| Forecast \| Maximum
Subsequent Events
Clinical trial cost \| $						$ 3,000,000
Subsequent Events \| At The Market Sales Agreement
Subsequent Events
Common stock, par value (in dollars per share)			$ 0.00001
Sales agent commission (in percentage)			2
Subsequent Events \| July 27, 2026 Registered direct offering
Subsequent Events
Securities purchase agreement, threshold restriction period		60 days
Securities purchase agreement, registration statement filing period		30 days
Gross proceeds \| $	$ 3,800,000
Subsequent Events \| July 27, 2026 Registered direct offering \| Pre-Funded Warrants
Subsequent Events
Warrants to purchase additional shares (in shares) \| shares		100,000
Warrant issued price (in dollars per share)		$ 1.52999
Number of shares issuable upon exercise of each warrants issued \| shares		1
Exercise price (in dollars per share)		$ 0.00001
Subsequent Events \| July 27, 2026 Registered direct offering \| Common Warrants
Subsequent Events
Warrants to purchase additional shares (in shares) \| shares		2,516,339
Number of shares issuable upon exercise of each warrants issued \| shares		1
Exercise price (in dollars per share)		$ 1.75
Warrant term		5 years 6 months
Subsequent Events \| Common Stock \| July 27, 2026 Registered direct offering
Subsequent Events
Common stock, par value (in dollars per share)		$ 0.00001
Number of shares to be issued (in shares) \| shares		2,416,339
Public offering price (in dollars per share)		$ 1.53